Combivir and efavirenz

PreclinicalSmall molecule

UUniversity of Oxford

Combivir and efavirenz is one of 11 small molecule programs targeting Meningitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MeningitisActive, not recruiting

MeningitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Meningitis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

2 2

Doribax

Rifadin

Cubicin

BBaxter Healthcare Corporation

Approved

—5

Sporanox

SSebela Pharmaceuticals Development LLC

Zyvox

4 7

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 2

1 8

Thiamine

UUniversiti Kebangsaan Malaysia Medical Centre

Phase 2

1 9

Contezolid

BBin Cao

Phase 2

1 10

Nexavar

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Meningitis1 trial

Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis

Unknown status·UUniversity of Oxford·N/A·NCT00433719·253 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Combivir and efavirenz. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combivir and efavirenz compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combivir and efavirenz. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Oxford company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Oxford

Combivir and efavirenz

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Meningitis1 trial

References

Drug Info

Quick Facts

Related News